The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

ProteoSys AG offers biotechnology research services. It provides solutions for the drug development process focusing on target system discovery, target validation, modes of action, studies of side effects and toxicology. The company was founded by Andr�� Schrattenholz and Helmut Matthies in 2000 and is headquartered in Mainz, Germany.

Far East Super Laboratories Ltd. is a private company headquartered in China that operates testing laboratories.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

Exact Sciences Development Co. LLC, part of EXACT Sciences Corp., is an American company. The firm engages in research and development diagnostic test for cancer.

Qurin Diagnostics BV develops diagnostic devices to non invasively detect early stage cancer of multiple types. The company was founded by Roderik Kraaijenhagen and is headquartered in Enschede, the Netherlands.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Genomictree Inc. is a company based out of South Korea.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Part of University of Adelaide, Adelaide Research & Innovation Pty Ltd. is an Australian company located in Adelaide. The firm provides analytical research services. Robert Chalmers is the current CEO of the firm.

Chengdu Doumai Technology Co., Ltd., established on 2021-01-18, Business scope includes licensed projects:Internet Live Streaming Service(Excluding news information service,web show,Internet audiovisual programs);Internet information service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:software development;Car rental;Charging pile sales;internet sales(Except for products that require a license for sale);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Advertising Design,acting;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);advertisement making;graphic design;Daily necessities wholesale;Daily necessities sales;Labor service(Does not include labor dispatch);IoT application service;Artificial intelligence innovation and innovation service platform;internet data service;Software outsourcing service;Artificial intelligence application software development;Artificial intelligence theory and algorithm software development;Network and Information Security Software Development;Research and development of intelligent robots;Network Equipment Sales;Computer and communication equipment rental(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.